Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) filed a Current Report on Form 8-K dated July 2, 2020. The filing reports the entry into a material definitive agreement to facilitate future equity financing.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on the authorization of a new capital raising mechanism.
Material Changes
On July 2, 2020, the Company entered into an At-The-Market (ATM) Sales Agreement with BTIG, LLC. Key terms include:
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $50,000,000.
- Role of Agent: BTIG will act as sales agent and/or principal.
- Commission: BTIG is entitled to a fixed commission rate of 3.0% of the gross proceeds from sales.
- Flexibility: The Company is not obligated to sell any shares and may determine sales based on market conditions and capital needs.
Guidance, Outlook, and Risks
Management Commentary: The Company retains sole discretion to terminate the Sales Agreement at any time with 5 days' prior notice. Sales are subject to customary conditions, including the effectiveness of the Registration Statement on Form S-3.
Risks and Contingencies: The filing notes that BTIG is not obligated to purchase shares on a principal basis. The agreement includes customary indemnification and contribution rights for BTIG and its affiliates regarding liabilities under the Securities Act.
Investor Verification Checklist
- Verify the effectiveness of the Form S-3 Registration Statement filed on July 2, 2020, which is a condition precedent to sales.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM program.
- Review the full text of the Sales Agreement (Exhibit 1.01) for specific limitations on the amount of stock that may be sold daily or in aggregate.
- Assess the impact of the 3.0% commission on net proceeds should the Company utilize the full $50,000,000 capacity.